文献速递免疫规划

通过糖工程改造冠状病毒糖盾呈递α-半乳糖表位以增强COVID-19疫苗免疫原性

Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.
PubMed 文献 · Vaccine · 2020-08-19

本文综述提出,SARS-CoV-2及其S蛋白表面的糖盾可遮蔽抗原肽并降低灭活病毒或S蛋白疫苗被抗原呈递细胞(APC)的摄取。基于灭活流感病毒和HIV gp120疫苗的小鼠研究,将糖盾糖工程化以呈递α-gal表位(Galα1-3Galβ1-4GlcNAc-R),可利用天然抗Gal抗体形成免疫复合物,经APC的Fc受体介导大幅增强疫苗摄取,使抗病毒免疫应答提高10-200倍、致死剂量活流感病毒攻击后存活率提高8倍。作者建议对灭活SARS-CoV-2或S蛋白疫苗的糖链进行类似糖工程改造以呈递α-gal表位,可能获得更强保护。

要点

  • 糖盾遮蔽抗原肽并降低灭活病毒或S蛋白疫苗被APC摄取。
  • α-gal表位可结合天然抗Gal抗体,形成免疫复合物靶向APC的Fc受体。
  • 小鼠研究中该策略使抗病毒应答提高10-200倍、存活率提高8倍。

核心结论

  • 将冠状病毒疫苗糖盾糖工程化以呈递α-gal表位,可能通过抗Gal抗体介导的APC摄取增强而提升COVID-19疫苗效力。

研究设计与样本

  • 本文为综述,汇总灭活流感病毒和HIV gp120疫苗的小鼠研究证据,并提出对SARS-CoV-2疫苗的糖工程改造策略。

主要发现

  • 灭活流感病毒和HIV gp120疫苗糖工程化呈递α-gal表位后,抗Gal抗体在接种部位结合疫苗形成免疫复合物,经APC的Fc受体介导被大量摄取。
  • 在小鼠中,该策略使抗病毒免疫应答较缺乏α-gal表位的相同疫苗提高10-200倍。
  • 在小鼠中,致死剂量活流感病毒攻击后存活率较缺乏α-gal表位的相同疫苗提高8倍。

关键数值与推荐

  • α-gal表位为Galα1-3Galβ1-4GlcNAc-R,是天然抗Gal抗体的配体,后者约占人免疫球蛋白的1%。

临床怎么用

  • 可考虑用重组α1,3半乳糖基转移酶、稳定转染GGTA1基因的高α1,3半乳糖基转移酶活性细胞中复制病毒、或含该基因的复制缺陷腺病毒转导宿主细胞,在冠状病毒疫苗上合成α-gal表位。
  • 也可在含相应糖基转移酶的糖工程化酵母或细菌表达系统中生产呈递多个α-gal表位的重组S蛋白。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The many carbohydrate chains on Covid-19 coronavirus SARS-CoV-2 and its S-protein form a glycan-shield that masks antigenic peptides and decreases uptake of inactivated virus or S-protein vaccines by APC. Studies on inactivated influenza virus and recombinant gp120 of HIV vaccines indicate that glycoengineering of glycan-shields to present α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) enables harnessing of the natural anti-Gal antibody for amplifying vaccine efficacy, as evaluated in mice producing anti-Gal. The α-gal epitope is the ligand for the natural anti-Gal antibody which constitutes ~1% of immunoglobulins in humans. Upon administration of vaccines presenting α-gal epitopes, anti-Gal binds to these epitopes at the vaccination site and forms immune complexes with the vaccines. These immune complexes are targeted for extensive uptake by APC as a result of binding of the Fc portion of immunocomplexed anti-Gal to Fc receptors on APC. This anti-Gal mediated effective uptake of vaccines by APC results in 10-200-fold higher anti-viral immune response and in 8-fold higher survival rate following challenge with a lethal dose of live influenza virus, than same vaccines lacking α-gal epitopes. It is suggested that glycoengineering of carbohydrate chains on the glycan-shield of inactivated SARS-CoV-2 or on S-protein vaccines, for presenting α-gal epitopes, will have similar amplifying effects on vaccine efficacy. α-Gal epitope synthesis on coronavirus vaccines can be achieved with recombinant α1,3galactosyltransferase, replication of the virus in cells with high α1,3galactosyltransferase activity as a result of stable transfection of cells with several copies of the α1,3galactosyltransferase gene (GGTA1), or by transduction of host cells with replication defective adenovirus containing this gene. In addition, recombinant S-protein presenting multiple α-gal epitopes on the glycan-shield may be produced in glycoengineered yeast or bacteria expression systems containing the corresponding glycosyltransferases. Prospective Covid-19 vaccines presenting α-gal epitopes may provide better protection than vaccines lacking this epitope because of increased uptake by APC.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Galili U. Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes. Vaccine. 2020. PMID: 32907757. doi:10.1016/j.vaccine.2020.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。